✦ LIBER ✦

G.P.11.05 The pharmacological chaperone AT2220 increases trafficking, processing, and cellular activity of acid α-glucosidase and is a potential new treatment for Pompe disease

✍ Scribed by A.C. Powe; J.F. Flanagan; R. Khanna; X. Wu; W. Liang; R. Dhulipala; T. Yin; K. Tang; R. Soska; L. Pellegrino; S. Shao; E.R. Benjamin; K.J. Valenzano; B.A. Wustman; D.J. Lockhart; H.V. Do

Book ID: 116793677
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 49 KB
Volume: 18
Category: Article
ISSN: 0960-8966
DOI: 10.1016/j.nmd.2008.06.265

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

G.P.8.05 The pharmacological chaperone A

G.P.8.05 The pharmacological chaperone AT2220 increases mutant acid alpha-glucosidase levels and reduces tissue glycogen in a mouse model of Pompe disease

✍ R. Khanna; R. Soksa; J. Feng; Y. Lun; A.C. Powe; J. Flanagan; H. Do; D.J. Lockha 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 39 KB

M.P.5.09 Pharmacological chaperone thera

M.P.5.09 Pharmacological chaperone therapy for the treatment of Pompe disease: Deoxynojirimycin increases lysosomal levels and specific activity of acid alpha-glucosidase

✍ B. Wustman; A. Powe Jr.; J. Flanagan; R. Khanna; W. Liang; X. Wu; R. Dhulipala; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 62 KB

T.P.44 The pharmacological chaperone AT2

T.P.44 The pharmacological chaperone AT2220 increases the stability of recombinant human acid α-glucosidase and leads to greater tissue uptake and glycogen reduction in a mouse model of Pompe disease

✍ Valenzano, K.J.; Feng, J.; Soska, R.; Pellegrino, L.; Frascella, M.; Lun, Y.; Fl 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB